The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21.1 - Manufacture of basic pharmaceutical products
100 - 106 jobs Number of planned job losses
Announcement Date
4 April 2025
Employment effect (start)
30 June 2025
Foreseen end date
30 July 2026
Description
Merck the German pharmaceutical group, announced around a 100 job cuts on the 17th of January in its French site in Gironde. On this site two branches operate: Life Science and Healthcare. They work on the development of biological molecules and active ingredients used in oncology treatments/
This decision is motivated by the company's restructuring activities in France. After a disengagement of an essential client - Fresenius Kabi that modified its contract of approvisionnement - Merck is going to supply them until summer 2026 and not 2030.
Frédéric Guichard an employee and union representative of Force ouvrière (FO) underlines the failure of the company's strategy to find new clients. On the 1st of august 2025 the Life Science subsidiary is going to be bought by the American research Lab AbbVie.
Eurofound (2025), Merck, Internal restructuring in France, factsheet number 202623, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/202623.